Bharat Biotech  

With this approval, Bharat Biotech achieved another significant milestone in innovating and manufacturing vaccines at global quality standards and moving forward in the ongoing fight against the Covid-19 pandemic, read Bharat Biotech statement.

America’s top pandemic expert Anthony Fauci said that Bharat Biotech’s Covaxin developed in India was found to neutralise B.1.617 variant or the Indian double mutant strain of the Covid-19 virus 
 

Managing director of Bharat Biotech Dr Krishna Ella has said that the biotechnological company’s nasal vaccine for Covid-19 is currently under its phase 1 trial 
 

An Indian Council of Medical Research study has shown that Bharat Biotech's Covaxin can effectively neutralise multiple variants of SARS-CoV-2 as well as the double mutant strain
 

Bharat Biotech, the producer of Covaxin has ramped up its production capacity to 700 million doses per annum 

Bharat Biotech’s vaccine – Covaxin – enjoys clinical success of 81% after phase 3 trials

British Medical Journal Lancet has jumped to the defence of India, asserting that Bharat Biotech's Covid-19 vaccine, Covaxin, is safe and generated immune response in the participants of the vaccine's phase-1 trials
 

Covaxin, Bharat Biotech’s coronavirus vaccine has shown promising results

 Bharat Biotech is planning to launch its vaccine for COVID-19 in the second quarter next year if it gets the requisite approvals from the Indian regulatory authorities

Currently, two indigenously developed vaccine candidates, one by Bharat Biotech in collaboration with ICMR and the other by Zydus Cadila Ltd, are in phase 2 of the human clinical trials

The Indian Council of Medical Research (ICMR) on Thursday said that it has partnered with Bharat Biotech International Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID Vaccine)